Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

NCT03958123 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Prolonged QTc Interval
Pharmacokinetic

Interventions

DRUG: 100 μg cebranopadol
DRUG: 200 μg cebranopadol
DRUG: 400 μg cebranopadol
DRUG: Placebo to cebranopadol encapsulated tablets
DRUG: 400 mg Moxifloxacin
DRUG: Placebo to moxifloxacin encapsulated tablets

Sponsor

Tris Pharma, Inc.

Collaborators

[object Object]